Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Contenuto fornito da Proactive Investors. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Proactive Investors o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !
Vai offline con l'app Player FM !
Just the Facts: Tryptamine Therapeutics’ TRP-8803 clears Phase 1b safety trial
Manage episode 445678346 series 2891889
Contenuto fornito da Proactive Investors. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Proactive Investors o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Proactive’s Tylah Tully breaks down Just the Facts of the latest news from Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF). The company has successfully completed the safety evaluation for its intravenous psilocin formulation, TRP-8803, following a Phase 1b clinical trial. This milestone demonstrates that the treatment was generally safe and well-tolerated, paving the way for further clinical studies. The trial began in June 2024 at CMAX Clinical Research in Adelaide and involved eleven healthy participants who received varying doses of the IV-infused psilocin over a period of up to 150 minutes. The result marks a significant step in Tryptamine's clinical program and will guide the design of upcoming Phase 2 trials. The company plans to build on its earlier success with the oral formulation, TRP-8802, which has shown potential in treating Binge Eating Disorder and Fibromyalgia. The intravenous version, TRP-8803, is expected to provide several advantages over oral psilocybin, such as a faster onset, shorter duration and better control over the therapeutic experience. The next phase will involve additional trials and ongoing regulatory engagement. #ProactiveInvestprs #TryptamineTherapeutics #ASX #JusttheFacts #PsilocybinTherapy #Phase1Trial #TRP8803 #PsilocinFormulation #SafetyEvaluation #BingeEatingDisorder #FibromyalgiaTreatment #PsychedelicTherapy #ClinicalTrials #Pharmacokinetics #PsilocybinResearch #HealthcareInnovation #CMAXResearch #MentalHealth #PsilocybinInfusion #SRCApproval #PsilocybinTherapeutics #TRP8802 #ClinicalDevelopment
…
continue reading
605 episodi
Manage episode 445678346 series 2891889
Contenuto fornito da Proactive Investors. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Proactive Investors o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Proactive’s Tylah Tully breaks down Just the Facts of the latest news from Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF). The company has successfully completed the safety evaluation for its intravenous psilocin formulation, TRP-8803, following a Phase 1b clinical trial. This milestone demonstrates that the treatment was generally safe and well-tolerated, paving the way for further clinical studies. The trial began in June 2024 at CMAX Clinical Research in Adelaide and involved eleven healthy participants who received varying doses of the IV-infused psilocin over a period of up to 150 minutes. The result marks a significant step in Tryptamine's clinical program and will guide the design of upcoming Phase 2 trials. The company plans to build on its earlier success with the oral formulation, TRP-8802, which has shown potential in treating Binge Eating Disorder and Fibromyalgia. The intravenous version, TRP-8803, is expected to provide several advantages over oral psilocybin, such as a faster onset, shorter duration and better control over the therapeutic experience. The next phase will involve additional trials and ongoing regulatory engagement. #ProactiveInvestprs #TryptamineTherapeutics #ASX #JusttheFacts #PsilocybinTherapy #Phase1Trial #TRP8803 #PsilocinFormulation #SafetyEvaluation #BingeEatingDisorder #FibromyalgiaTreatment #PsychedelicTherapy #ClinicalTrials #Pharmacokinetics #PsilocybinResearch #HealthcareInnovation #CMAXResearch #MentalHealth #PsilocybinInfusion #SRCApproval #PsilocybinTherapeutics #TRP8802 #ClinicalDevelopment
…
continue reading
605 episodi
Усі епізоди
×Benvenuto su Player FM!
Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.